JP2015516156A5 - - Google Patents

Download PDF

Info

Publication number
JP2015516156A5
JP2015516156A5 JP2015509008A JP2015509008A JP2015516156A5 JP 2015516156 A5 JP2015516156 A5 JP 2015516156A5 JP 2015509008 A JP2015509008 A JP 2015509008A JP 2015509008 A JP2015509008 A JP 2015509008A JP 2015516156 A5 JP2015516156 A5 JP 2015516156A5
Authority
JP
Japan
Prior art keywords
protein
cells
isolated
cell
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015509008A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015516156A (ja
JP6258922B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/036175 external-priority patent/WO2013162905A1/en
Publication of JP2015516156A publication Critical patent/JP2015516156A/ja
Publication of JP2015516156A5 publication Critical patent/JP2015516156A5/ja
Application granted granted Critical
Publication of JP6258922B2 publication Critical patent/JP6258922B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015509008A 2012-04-25 2013-04-11 制御性b細胞の製造及び使用方法 Active JP6258922B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261637915P 2012-04-25 2012-04-25
US61/637,915 2012-04-25
PCT/US2013/036175 WO2013162905A1 (en) 2012-04-25 2013-04-11 Methods of producing and using regulatory b-cells

Publications (3)

Publication Number Publication Date
JP2015516156A JP2015516156A (ja) 2015-06-11
JP2015516156A5 true JP2015516156A5 (enExample) 2016-05-19
JP6258922B2 JP6258922B2 (ja) 2018-01-10

Family

ID=48183014

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015509008A Active JP6258922B2 (ja) 2012-04-25 2013-04-11 制御性b細胞の製造及び使用方法

Country Status (6)

Country Link
US (1) US9629897B2 (enExample)
EP (1) EP2841562B1 (enExample)
JP (1) JP6258922B2 (enExample)
AU (1) AU2013252771B2 (enExample)
CA (1) CA2871499C (enExample)
WO (1) WO2013162905A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2890691B1 (en) * 2012-08-31 2018-04-25 Principia Biopharma Inc. Benzimidazole derivatives as itk inhibitors
WO2018013897A1 (en) * 2016-07-15 2018-01-18 Board Of Regents, The University Of Texas System Regulatory b cells and uses thereof
GB201707238D0 (en) 2017-05-05 2017-06-21 Univ Oxford Innovation Ltd Composition
AU2018288863A1 (en) * 2017-06-22 2020-01-30 Board Of Regents, The University Of Texas System Methods for producing regulatory immune cells and uses thereof
CA3107687A1 (en) * 2018-02-26 2019-08-29 Claudia Zylberberg Immune cell activation
CA3136551A1 (en) 2019-04-12 2020-10-15 Board Of Regents, The University Of Texas System Methods for producing regulatory b cells and uses thereof
AU2020295470B2 (en) 2019-06-18 2025-10-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Interleukin-27 producing B-cells and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2560525A1 (en) 2004-03-18 2005-09-29 The University Court Of The University Of Glasgow Immunosuppressive cytokine
BRPI0610824A8 (pt) 2005-05-16 2017-04-04 Prometic Pharma Smt Ltd Compostos derivados de purina, uso dos mesmos e composição contendo os referidos compostos
CA2722184A1 (en) * 2008-04-25 2009-10-29 Duke University Regulatory b cells and their uses
EP2547328B1 (en) * 2010-02-11 2017-06-07 Ecole Polytechnique Fédérale de Lausanne (EPFL) Ccr7 ligand delivery and co-delivery in immunotherapy
WO2012082771A1 (en) * 2010-12-13 2012-06-21 The Board Of Trustees Of The Leland Stanford Junior University Cardiac glycosides for treating autoimmune disease

Similar Documents

Publication Publication Date Title
PH12018501335A1 (en) Novel generation of antigen-specific tcrs
CY1122386T1 (el) Χιμαιρικος υποδοχεας αντιγονων και μεθοδοι χρησης εξ αυτου
Coetzee et al. A review of experimental infections with bluetongue virus in the mammalian host
CL2016003096A1 (es) Métodos para cosechar cultivos de células de mamífero
SG195306A1 (en) Purification of biological products by constrained cohydration chromatography
JP2016104045A5 (enExample)
ME03796B (me) Anti-lag-3 vezujući proteini
MY167722A (en) Car expression vector and car-expressing t cells
MX389758B (es) Ratones con genes insertados de sirpa-il15 humanizadas y métodos para usarlos
CR20140565A (es) Proteínas de fusión de interleuquina 10 y usos de las mismas
AU2013211059A8 (en) Targeted mutant alpha-helical bundle cytokines
EP4218409A3 (en) Mice expressing a limited immunoglobulin light chain repertoire
WO2009091912A3 (en) Improved mammalian expression vectors and uses thereof
JP2011136997A5 (enExample)
HRP20170468T1 (hr) Bispecifična protutijela protiv baff i protiv il-17
IL274082A (en) Systems and methods for the production of genetically modified B cells for the expression of selected antibodies
JP2016501515A5 (enExample)
Quesnel CAR T-cells: A John von Neumann legacy?
WO2013162905A8 (en) Methods of producing and using regulatory b-cells
EP2600894A4 (en) MODIFIED HEPATITIS C VIRUS PROTEINS
WO2015003160A3 (en) Hepatocytes in co-culture and uses thereof
Münz Natural killer cell responses during human γ-herpesvirus infections
JP2013529900A5 (enExample)
Scaria Joining the long shots: emerging evidence on the role of long noncoding RNAs in rheumatoid arthritis
MX384990B (es) Selectividad eficaz de proteínas recombinantes.